The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

December 20, 2017 • By Catherine Kolonko

  • Tweet
  • Email
Print-Friendly Version / Save PDF

More children received cyclophosphamide than rituximab (57% vs. 21%), and 10% received a combination of both. However, the use of rituximab increased over time, notably beginning in 2011, one year after the 2010 landmark studies, says Dr. James. “We did see rituximab use was more common in hospitals that had a higher volume of ANCA vasculitis patients,” she says. “We viewed that as a marker of familiarity with treating patients. So the more patients they treated, the more likely they were to use rituximab.”

You Might Also Like
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
Explore This Issue
December 2017

The researchers used mechanical ventilation and dialysis as surrogate markers for the severe disease manifestations of renal failure and respiratory failure. Roughly 15% of the study’s patients required dialysis, and 17% needed mechanical ventilation. Researchers found that 21% of the patients received plasma exchange and that its use was highly variable and associated with needing dialysis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The treatment of children with severe AAV is shifting from cyclophosphamide to rituximab, and their need for dialysis, mechanical ventilation and prolonged hospitalization remains common,” the article concluded. “Use of plasma exchange is highly variable.”

Going Forward

Dr. James says the study gives pediatricians “great understanding” of the illness severity and variability that exists in this pediatric population. “I think this research helps show other providers that yes, people are adopting rituximab, and it’s OK to do that,” she says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We have a lot of work to do in … figuring out what is best for kids so that people feel comfortable using these regimens,” she says. “Something needs to be done to treat these kids because they are so sick.”


Catherine Kolonko is a medical writer based in Oregon.

References

  1. James KE, Xiao R, Merkel PA, et al. Variation in the treatment of children hospitalized with antineutrophil cytoplasmic antibody–associated vasculitis in the United States. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1377–1383.
  2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221–232.
  3. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomized trial. Ann Rheum Dis. 2015 Jun;74(6):1178–1182.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: AAV, AC&R, American College of Rheumatology, antibody-associated vasculitis, Arthritis Care & Research, Children, Clinical, cyclophosphamide, Diagnosis, drug, outcome, patient care, Pediatric, Research, rheumatologist, rheumatology, rituximab, study, therapy, treament, VasculitisIssue: December 2017

You Might Also Like:
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
  • Latest Research on Cutaneous Vasculitis Diagnosis, Treatment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)